- Conditions
- Tumors, Lymphoma, Multiple Myeloma
- Interventions
- ridaforolimus
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Malignant Glioma, Glioblastoma, Gliosarcoma
- Interventions
- AP23573
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Cleveland, Ohio + 1 more
- Conditions
- Endometrial Cancer, Ovarian Cancer
- Interventions
- Ridaforolimus, Paclitaxel, carboplatin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Heart Disease
- Interventions
- BioNIR Ridaforolimus Eluting Coronary Stent
- Device
- Lead sponsor
- Medinol Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Petoskey, Michigan
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ridaforolimus
- Drug
- Lead sponsor
- Angela Taber MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Pawtucket, Rhode Island • Providence, Rhode Island
- Conditions
- Superficial Femoral Artery Stenosis, Popliteal Artery Stenosis
- Interventions
- ChampioNIR Ridaforolimus Eluting Peripheral Stent System
- Device
- Lead sponsor
- Medinol Ltd.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • New York, New York • Roslyn, New York
- Conditions
- Prostate Cancer
- Interventions
- ridaforolimus
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • Houston, Texas + 1 more
- Conditions
- Coronary Artery Stenosis
- Interventions
- BioNIR, Resolute
- Device
- Lead sponsor
- Medinol Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,919 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Coronary Stenosis, Coronary Artery Disease
- Interventions
- IoNIR Ridaforolimus-Eluting Coronary Stent System
- Device
- Lead sponsor
- Medinol Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Roslyn, New York
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ridaforolimus, vorinostat, biopsy, pharmacological study, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rockledge, Pennsylvania
- Conditions
- Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes, Myeloid Metaplasia, Lymphoma
- Interventions
- ridaforolimus
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • St Louis, Missouri • New Brunswick, New Jersey + 5 more
- Conditions
- Soft Tissue Sarcoma
- Interventions
- ridaforolimus
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas